Mangini Siobhan Nolan - Mar 2, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
President and CFO
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 04:12 PM
Previous filing
Jul 1, 2022
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Award $0 +76K $0.00 76K Mar 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +228K $0.00 228K Mar 2, 2023 Common Stock 228K $4.36 Direct F2
transaction NGM Stock Option (Right to Buy) Award $0 +200K $0.00 200K Mar 2, 2023 Common Stock 200K $4.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2 The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F3 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.